Evidence map›Paper›PMID 36138656›Full record

ArticleChildren (Basel, Switzerland)2022

The Economic Burden of Pneumococcal Disease in Children: A Population-Based Investigation in the Veneto Region of Italy.

Elisa Barbieri, Gloria Porcu, Tanaz Petigara, Francesca Senese, Gian Marco Prandi, Antonio Scamarcia, Luigi Cantarutti, Anna Cantarutti, Carlo Giaquinto

Abstract read
In one paragraph

Article in Children (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Trends in the incidence and burden of otitis media in children: a global analysis from 1990 to 2021.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2025
    Article
  3. Article
  4. New insights into the treatment of acute otitis media.Expert review of anti-infective therapy · 2023
    Review
  5. [The new 15-valent pneumococcal conjugate vaccine for the prevention ofJournal of preventive medicine and hygiene · 2023
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Elisa BarbieriDivision of Pediatric Infectious Diseases, Department of Women's and Children's Health, University of Padova, 35131 Padova, Italy.ORCID 0000-0003-0850-8784
Gloria PorcuUnit of Biostatistics Epidemiology and Public Health, Department of Statistics and Quantitative Methods, University of Milano-Bicocca, 20126 Milan, Italy.ORCID 0000-0002-9871-4129
Tanaz PetigaraCenter for Observational and Real-World Evidence, Merck & Co., Inc., Rahway, NJ 07065, USA.
Francesca SeneseMSD Italy, 00189 Rome, Italy.
Gian Marco PrandiMSD Italy, 00189 Rome, Italy.
Antonio ScamarciaPedianet Project, 35138 Padova, Italy.
Luigi CantaruttiPedianet Project, 35138 Padova, Italy.
Anna CantaruttiUnit of Biostatistics Epidemiology and Public Health, Department of Statistics and Quantitative Methods, University of Milano-Bicocca, 20126 Milan, Italy.ORCID 0000-0002-3700-780X
Carlo GiaquintoDivision of Pediatric Infectious Diseases, Department of Women's and Children's Health, University of Padova, 35131 Padova, Italy.

Funding

Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA NA
6 · The paper itself

Abstract

Despite widespread childhood immunization programs, pneumococcal disease (PD) continues to be associated with significant clinical and economic burden worldwide. This retrospective study assessed the PD-related economic burden in children from the Veneto region of Italy following the introduction of a 13-valent pneumococcal conjugate vaccine (PCV13) to the Italian immunization schedule in 2010. Between 2010 and 2017, the annual incidences of pneumonia, acute otitis media (AOM), and invasive pneumococcal disease (IPD), as well as syndromic-disease-related episodes, declined. In our analysis of data from regional expenditure and healthcare resource utilization (HCRU) databases related to children < 15 years of age, we found that regional expenditures decreased between 2010 and 2017 for pneumonia (EUR 8.88 to EUR 3.59 million), AOM (EUR 3.78 to EUR 2.76 million), and IPD (EUR 1.40 to EUR 1.00 million). Despite reductions in PD-related expenditure following the introduction of PCV13, there continues to be an economic burden associated with PD in Veneto, Italy.

Indexed as

acute otitis mediaeconomic burdenhealthcare resource utilizationinvasive pneumococcal diseaseItalypneumococcal diseasepneumonia

Identifiers

PMID36138656
PMCPMC9498138

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.